Investigational drug · Phase 2
ICT01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ICT01"
First trial start
2020
Mar 5, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ICT01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor, Adult
- Hematopoietic/Lymphoid Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ICT01" as an intervention, largest first.
- A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive ChemotherapyPivotal-lookingNot yet recruiting
IpsenIndustry
NCT07623187 · 540 participants (planned) · Start Nov 1, 2026 · Primary completion May 31, 2031
Drug: IPN60340 + azacitidine + venetoclax; Placebo + azacitidine + venetoclax · For: Acute Myeloid Leukaemia (AML); Acute Myeloid Leukaemia
- First-in-Human Study of ICT01 in Patients With Advanced CancerPivotal-lookingActive, not recruiting
ImCheck Therapeutics, an Ipsen companyIndustry
NCT04243499 · 293 participants · Start Mar 5, 2020 · Primary completion Oct 15, 2027
Drug: IV ICT01 · For: Solid Tumor, Adult; Hematopoietic/Lymphoid Cancer
Sites: Gilbert, Arizona; Duarte, California; New Haven, Connecticut · 29 sites in all
ImCheck Therapeutics, an Ipsen companyIndustry
NCT05307874 · 56 participants · Start May 4, 2022 · Primary completion Oct 9, 2025
Drug: ICT01; Proleukin Injectable Product and 1 more · For: Solid Tumor, Adult
Sites: Paris, France; Toulouse, France; Dresden, Germany · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Kinetic Modeling and Radiomics Analysis of the Heterogeneity of Tumor-Associated Macrophages and Metabolism in Head and Neck Cancer.
Nai YH, Heo GS, Madrid P, et al. · Chem Biomed Imaging 2026
- Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response.
De Gassart A, Le KS, Brune P, et al. · Sci Transl Med 2021
- Immunotherapy Activates Antitumor γ9δ2 T Cells.
· Cancer Discov 2021
- Characterisation of aggregates of cyclodextrin-drug complexes using Taylor Dispersion Analysis.
Zaman H, Bright AG, Adams K, et al. · Int J Pharm 2017
Also in development for Solid Tumor, Adult
- VisugromabCTL-002, Visugromab RDEPhase 36 trials
CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma
- anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials
Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- CRB-701Phase 32 trials
Corbus Pharmaceuticals Inc. · Solid Tumor, Adult, Oropharyngeal Carcinoma (OPC)
- HMPL-453Phase 32 trials
Hutchmed · Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult, Solid Tumor
- VT3989Phase 32 trials
Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult
- DabogratinibTYRA-300Phase 24 trials
Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia
- VS-7375Phase 24 trials
Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- Tmod CAR T-cell TherapyA2B530, A2B694Phase 23 trials
A2 Biotherapeutics Inc. · Solid Tumor, Adult, Colorectal Cancer, Colorectal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.